Document Type
Article (Restricted)
Publication Date
1-1-2002
Abstract
Purpose: To assess the long-term survival of patients with nasopharyngeal carcinoma (NPC) who were treated with conventional radical radiotherapy (RT) followed by adjuvant chemotherapy. Methods and Materials: Ninety-one newly diagnosed patients with Stage III and IV (American Joint Committee on Cancer, 1988) NPC, seen at the University of Malaya Medical Center, Kuala Lumpur, Malaysia between January 1992 and May 1997, were treated with RT followed by adjuvant chemotherapy. The tumor dose was 70 Gy delivered in 35 fractions, 5 fractions weekly. Three cycles of chemotherapy, each consisting of 5-fluorouracil, 1 g/m(2)/d on Days 1-4 and cisplatin 100 mg/m(2) on Day 1, were administered 3 weeks after RT completion. Thirty-six patients had Stage 11, 10 had Stage III, and 45 had Stage IV disease (AJCC 1997 staging system). Results: After a median follow-up of 61 months, the 5-year overall survival rate for all 91 patients was 80.1, the disease-free survival rate was 76, and the locoregional control rate was 85. The 3-year overall survival rate for Stage II was 94.3; it was 80 for Stage III and 79.8 for Stage IV (p = 0.0108). The 3-year DFS rate for Stage II was 90; it was 80 for Stage H and 65 for Stage IV. The rate of distant failure for Stage IV was 8.9. Conclusion: Radical RT followed by adjuvant chemotherapy was effective in our patients with locoregionally advanced NPC. The long-term results appear encouraging, even for patients with Stage IV disease. This single institution experience deserves further investigation in prospective trials.
Keywords
Nasopharyngeal carcinoma adjuvant chemotherapy long-term results concomitant radiotherapy chemoradiotherapy cancer
Divisions
fac_med
Publication Title
International Journal of Radiation Oncology Biology Physics
Volume
53
Issue
3
Publisher
Elsevier
Additional Information
ISI Document Delivery No.: 568JR Times Cited: 7 Cited Reference Count: 23 Cited References: Al-Sarraf M, 1998, J CLIN ONCOL, V16, P1310 ALSARRAF M, 2001, P AN M AM SOC CLIN, V20, P905 BEAHRS OH, 1988, MANUAL STAGING CANC, P33 CHAN ATC, 1995, INT J RADIAT ONCOL, V33, P569, DOI 10.1016/0360-3016(95)00218-N Cheng SH, 2000, J CLIN ONCOL, V18, P2040 Cheng SH, 2000, INT J RADIAT ONCOL, V48, P1323, DOI 10.1016/S0360-3016(00)00779-3 CHI KW, 2001, P AN M AM SOC CLIN, V20, P889 Cooper JS, 2000, INT J RADIAT ONCOL, V48, P1277, DOI 10.1016/S0360-3016(00)00778-1 Cooper JS, 2000, INT J RADIAT ONCOL, V47, P861, DOI 10.1016/S0360-3016(00)00558-7 COX DR, 1972, J ROY STAT SOC B, V34, P187 Fleming I, 1997, AJCC CANC STAGING MA, P31 Gabriele AM, 2000, TUMORI, V86, P399 KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868 Ma J, 2001, J CLIN ONCOL, V19, P1350 MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6 Ozyar E, 1999, INT J RADIAT ONCOL, V44, P1079, DOI 10.1016/S0360-3016(99)00098-X PEREZ CA, 1992, PRINCIPLES PRACTICE, P51 PRASAD U, 1999, P AM SOC CLIN ONCOL, V18, P1580 PRASAD U, 2000, P AM SOC CLIN ONCOL, V19, P1675 ROSENTHAL DI, 1994, INT J RADIAT ONCOL, V28, P315 ROSSI A, 1988, J CLIN ONCOL, V6, P1401 TEO P, 1989, INT J RADIAT ONCOL, V17, P515 *INT NAS CANC STUD, 1996, NT J RAD ONCOL BIOL, V35, P463 Prasad, U Wahid, MIA Jalaludin, MA Abdullah, BJJ Paramsothy, M Abdul-Kareem, S Elsevier science inc New york